Novo Nordisk A S
etavopivat
sickle cell disease
Countdown
177days
Approval decision · ~ Dec 31, 2026 estimated
What's at stake
A final FDA approval decision on etavopivat for sickle cell disease is expected ~ Dec 31, 2026.
Primary source
· SEC 6-K
verified 12h ago
“Novo Nordisk plans to submit for the first regulatory approval of etavopivat in the second half of 2026”